Bionaturis (ticker BNT-MAB), an international reference company developing biological drugs, has just acquired the San Sebastian-based company BBD BIOPHENIX S.L (BBD), a leader in state-of-the-art screening systems for drug discovery. With this acquisition Bionaturis incorporates cutting-edge biotech assets to its organic growth, in this case, related to the use of zebra fish models for early determination of drug pharmacological profiles.
BBD is an international leader in the field of using the zebra fish model for drug toxicity and efficacy tests applying the latest technologies such as image analysis and automation. This alternative model improves the cost/effectiveness of preclinical phase for pharmaceutical, biotechnology, petrochemical, agrochemical, and cosmetic companies. BBD has a wide portfolio of big pharma clients, from United States and Europe.
About the acquisition, Victor Infante –Bionaturis´ CEO- states: “This acquisition is important to the growth of Bionaturis, improving its services and clients portfolio at international level, but above all, it means to add talent on board. The intrinsic talent of BBD is a reference of leadership and result-achievement”.
Arantza Muriana, R & D Director and founding partner of BBD BioPhenix comments on the operation: “It will help us meet the goals of market diversification and international expansion marked by the company”. She also highlights the important synergies between the two companies.